Literature DB >> 14652710

Relationship between ecstasy use and depression: a study controlling for poly-drug use.

Jonathan P Roiser1, Barbara J Sahakian.   

Abstract

RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA or "ecstasy") causes serotonin neuron damage in laboratory animals. The serotonin system is known to be important in the regulation of mood. Previous research has shown that MDMA users score higher on self-report ratings of depression than controls. However, MDMA users commonly take other illicit substances and many studies do not fully control for poly-drug use.
OBJECTIVES: The aim of this study was to examine the relationship between MDMA use and affective disturbance, while fully controlling for poly-drug use.
METHODS: Participants were 30 current MDMA users, 30 poly-drug controls who had never used MDMA, 30 drug-naïve controls with no history of illicit drug use and 20 ex-MDMA users. The current MDMA users and poly-drug controls were well matched on all indices of non-MDMA drug use. All participants were administered the Beck Depression Inventory (BDI) and the Affective Go/No-go task, which has been shown to be sensitive to depression.
RESULTS: The current and ex-MDMA users scored significantly higher on the BDI than the drug-naive controls, but were not significantly different from the poly-drug controls. There were no differences between the groups in terms of affective bias scores on the Affective Go/No-go task.
CONCLUSIONS: Increased scores on self-report depression scales in MDMA users are not entirely attributable to MDMA use. MDMA users do not show the same attentional bias towards negatively toned material as depressed patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652710      PMCID: PMC2556104          DOI: 10.1007/s00213-003-1705-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  Selective attention to emotional stimuli in a verbal go/no-go task: an fMRI study.

Authors:  R Elliott; J S Rubinsztein; B J Sahakian; R J Dolan
Journal:  Neuroreport       Date:  2000-06-05       Impact factor: 1.837

2.  Acute dietary tryptophan depletion impairs maintenance of "affective set" and delayed visual recognition in healthy volunteers.

Authors:  J S Rubinsztein; R D Rogers; W J Riedel; M A Mehta; T W Robbins; B J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2001-03       Impact factor: 4.530

3.  Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users.

Authors:  A C Parrott; E Sisk; J J Turner
Journal:  Drug Alcohol Depend       Date:  2000-07-01       Impact factor: 4.492

4.  Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users.

Authors:  D M Semple; K P Ebmeier; M F Glabus; R E O'Carroll; E C Johnstone
Journal:  Br J Psychiatry       Date:  1999-07       Impact factor: 9.319

5.  Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion.

Authors:  K A Smith; J S Morris; K J Friston; P J Cowen; R J Dolan
Journal:  Br J Psychiatry       Date:  1999-06       Impact factor: 9.319

6.  Emotional bias and inhibitory control processes in mania and depression.

Authors:  F C Murphy; B J Sahakian; J S Rubinsztein; A Michael; R D Rogers; T W Robbins; E S Paykel
Journal:  Psychol Med       Date:  1999-11       Impact factor: 7.723

7.  Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons.

Authors:  L Reneman; J Booij; K de Bruin; J B Reitsma; F A de Wolff; W B Gunning; G J den Heeten; W van den Brink
Journal:  Lancet       Date:  2001-12-01       Impact factor: 79.321

8.  No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H2(15)O]-positron emission tomography study.

Authors:  A Gamma; A Buck; T Berthold; F X Vollenweider
Journal:  J Clin Psychopharmacol       Date:  2001-02       Impact factor: 3.153

9.  Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms.

Authors:  N MacInnes; S L Handley; G F Harding
Journal:  J Psychopharmacol       Date:  2001-09       Impact factor: 4.153

10.  Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans.

Authors:  G Gerra; A Zaimovic; M Ferri; U Zambelli; M Timpano; E Neri; G F Marzocchi; R Delsignore; F Brambilla
Journal:  Biol Psychiatry       Date:  2000-01-15       Impact factor: 13.382

View more
  19 in total

1.  The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.

Authors:  Maartje M L De Win; Gerry Jager; Hylke K E Vervaeke; Thelma Schilt; Liesbeth Reneman; Jan Booij; Frank C Verhulst; Gerard J Den Heeten; Nick F Ramsey; Dirk J Korf; Wim Van den Brink
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

2.  The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls.

Authors:  Jonathan P Roiser; Robert D Rogers; Lynnette J Cook; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2006-08-29       Impact factor: 4.530

3.  Emotion, decision-making and substance dependence: a somatic-marker model of addiction.

Authors:  A Verdejo-García; M Pérez-García; A Bechara
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

Review 4.  A somatic marker theory of addiction.

Authors:  Antonio Verdejo-García; Antoine Bechara
Journal:  Neuropharmacology       Date:  2008-08-05       Impact factor: 5.250

5.  Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).

Authors:  Lynn Taurah; Chris Chandler; Geoff Sanders
Journal:  Psychopharmacology (Berl)       Date:  2013-10-11       Impact factor: 4.530

6.  Perceived Parental Relationships and Health-Risk Behaviors in College-Attending Emerging Adults.

Authors:  Seth J Schwartz; Byron L Zamboanga; Russell D Ravert; Su Yeong Kim; Robert S Weisskirch; Michelle K Williams; Melina Bersamin; Gordon E Finley
Journal:  J Marriage Fam       Date:  2009-07-30

7.  Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.

Authors:  Krista Lisdahl Medina; Paula K Shear
Journal:  Drug Alcohol Depend       Date:  2006-10-30       Impact factor: 4.492

8.  Tri-city study of Ecstasy use problems: a latent class analysis.

Authors:  Lawrence M Scheier; Arbi Ben Abdallah; James A Inciardi; Jan Copeland; Linda B Cottler
Journal:  Drug Alcohol Depend       Date:  2008-07-31       Impact factor: 4.492

9.  Substance Use Correlates of Depression among African American Male Inmates.

Authors:  Rhonda Conerly Holliday; Ronald L Braithwaite; Elleen Yancey; Tabia Akintobi; Danielle Stevens-Watkins; Selina Smith; C Lamonte Powell
Journal:  J Health Care Poor Underserved       Date:  2016

10.  Ecstasy use and depression: a 4-year longitudinal study among an Australian general community sample.

Authors:  Amanda M George; Sarah Olesen; Robert J Tait
Journal:  Psychopharmacology (Berl)       Date:  2013-05-17       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.